Next 10 |
home / stock / pyxs / pyxs articles
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation ther...
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Re...
U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday. Shares of Signet Jewelers Limited (NYSE: SIG) rose sharply during ...
Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-than-expected se...
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: "PYXS"), a clinical stage company focused on developing next generation...
BOSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation th...
PYX-201, an EDB+FN-specific tumor stroma-targeting ADC, demonstrates potent anti-tumor efficacy across multiple human cancers in PDX tumor models ...
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. Helix Energy posted ...
BOSTON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company focused on developing next-generation the...
News, Short Squeeze, Breakout and More Instantly...
Pyxis Oncology Inc. Company Name:
PYXS Stock Symbol:
NASDAQ Market:
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical stage company focused on developing next generation ther...
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a...
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Re...